EMA

欧洲药品管理局（European Medicines Agency，EMA）成立于1995年的欧洲药品管理局，欧洲药品管理局负责泛欧洲范围的药品审批。

共 33 讨论,7天新增 28 个讨论,30天新增 28 个讨论

综合 问题 文章 百科
最新排序
热门排序
推荐内容
ki1314520ki1314520 回复了问题 2023-10-18 23:03
EMA EU_GMP
问答 基于问卷调查、文件评审、ISO 9000认证、分析测试结果和与供应商的历史经验进行远程评估是否可以接受?
ki1314520: EEA检查员通常不赞成“纸质审计”本身，因为它能提供与现场评估相同的保证水平，但确实接受它们在基于风险的战略中发挥作用。当最近的积极检查信息是可用的，并且在过去已经完成了令人满意的审核时，它们可能特别适用。它们不能取代对原料药供应商的现场审核，但可以作为制造商审核方案内的一项有用的临时和临时措施。
kk444555kk444555 回复了问题 2023-10-17 23:01
EMA
问答 How should design spaceverification approach be addressed in the pharmaceutical quality system?
kk444555: FDA recommends that firms have a writtenplan for when and how to evaluate the need for design space verification undertheir pharmaceutical quality sys...
kk444555kk444555 回复了问题 2023-10-17 23:01
EMA
问答 What is the difference betweenprocess validation and design space verification?
kk444555: Design space verification should not beconfused with process validation. Both take into consideration prior knowledgeand development conclusions and a...
kk444555kk444555 回复了问题 2023-10-17 23:00
EMA
问答 How can a design space beverified at commercial scale for biological products?
kk444555: Principles laid down for chemical productsare applicable to biological products. In addition, verification studies shouldprovide evidence that the qua...
kk444555kk444555 回复了问题 2023-10-17 22:59
EMA
问答 What if unexpectedresults/events are obtained during the design space verification studies?
kk444555: If the verification studies prove theprocess does not meet the predefined product quality attributes in a new regionof the approved design space, this...
kk444555kk444555 回复了问题 2023-10-17 22:58
EMA
问答 How should design spaceverification protocol be addressed in the submission?
kk444555: In principle, a design space verificationprotocol could include the following: list of scale dependent parameters whoseimpact on the CQAs has not been...
kk444555kk444555 回复了问题 2023-10-17 22:57
EMA
问答 How can a design space beverified at commercial scale?
kk444555: It is not necessary to repeat at commercialscale the experiments initially conducted to define a design space at labor pilotscale. Furthermore, it is ...
kk444555kk444555 回复了问题 2023-10-17 22:56
EMA
问答 How is a design space initiallydeveloped and verified at commercial scale?
kk444555: Both Agencies acknowledge that when adesign space is established at early stages of product development, it istypically developed based on experiments...
kk444555kk444555 回复了问题 2023-10-17 22:56
EMA
问答 What is the purpose of design spaceverification at commercial scale?
kk444555: Design space verification demonstrates thatwithin design space boundaries scale-up effects are under control and do notadversely affect the expected p...
kk444555kk444555 回复了问题 2023-10-17 22:54
EMA
问答 Why would a design space beverified during the product lifecycle?
kk444555: In both Agencies’ experience, the designspace verification at commercial scale is not necessarilycomplete at the time of submission of the application...
kk444555kk444555 回复了问题 2023-10-17 22:53
EMA
问答 在临床药品（IMP）开发阶段整个过程中是否要对HBEL进行重新评估？
kk444555: Health-Based Exposure Limits should be established based on all available data, and particularly as the knowledge base for IMPs is continually evolvin...
kk444555kk444555 回复了问题 2023-10-17 22:52
EMA
问答 在同一设施中生产不同物种的兽药时要考虑什么？
kk444555: The guideline on setting health-based exposure limits indicates that the carry over limit should generally be derived using the human HBEL.HBEL设定指南指出一...
kk444555kk444555 回复了问题 2023-10-17 22:52
EMA
问答 杀外寄生虫药物是否可以与其它类别人用或兽用药品在共用设备中生产或进行内包装？
kk444555: If a HBEL cannot be determined or data cannot support manufacture in shared facilities then the Ectoparasiticides should be manufactured in dedicated ...
kk444555kk444555 回复了问题 2023-10-17 22:51
EMA
问答 Is the use of LD50 to determine Health-Based Exposure Limits for drug products acceptable?
kk444555: No, LD50 is not an adequate point of departure to determine a HBEL for drug products.不可以，LD50用于计算药品HBEL是不充分的。
kk444555kk444555 回复了问题 2023-10-17 22:50
EMA
问答 简单地在专用区内生产同一类治疗用途的药品进行分隔作为交叉污染风险控制方式是否可接受？
kk444555:  Manufacturers cannot just segregate common products from other product types as a means of dealing with the risk to patient and animal safety. A...
发讨论
写文章
话题日志

相关话题

父话题
质量机构

3 人关注该话题

热门话题

有源医疗器械

MORE系统

菌种

8D报告

质量人指南

技术支持 WeCenter © 2024 粤ICP备2023143277号-1